Vaccines

14 pages, 2295 KiB

Open AccessArticle

4-1BBL-Armed Oncolytic Herpes Simplex Virus Exerts Antitumor Effects in Pancreatic Ductal Adenocarcinoma

by Wenrui Gao, Zhuoqian Zhao, Ying Bi, Jinghua Li, Na Tian, Cuizhu Zhang, Shuyuan Pan, Li Deng and Yuntao Zhang

Vaccines 2024, 12(12), 1309; https://doi.org/10.3390/vaccines12121309 - 22 Nov 2024

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a notably poor response to therapy due to its immunosuppressive tumor microenvironment (TME) and intrinsic drug resistance. The oncolytic virus (OV) represents a promising therapeutic strategy capable of transforming the “cold” immunological [...] Read more.

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a notably poor response to therapy due to its immunosuppressive tumor microenvironment (TME) and intrinsic drug resistance. The oncolytic virus (OV) represents a promising therapeutic strategy capable of transforming the “cold” immunological profile of PDAC tumors to a “hot” one by reshaping the TME. 4-1BB (CD137), a crucial member of the tumor necrosis factor receptor superfamily, plays a significant role in T-cell activation and function. Methods: In this study, we constructed an oncolytic herpes simplex virus armed with 4-1BBL (oHSV-4-1BBL), the ligand for the 4-1BB receptor, and investigated its therapeutic effects in two mouse models of pancreatic cancer, Pan02_HVEM and KPC. Results: We found that oHSV-4-1BBL remarkably inhibited tumor growth and extended the median survival time in both models. To amplify the therapeutic effect, we further combined oHSV-4-1BBL with PD-1 antibody. This combination therapy not only further suppressed tumor growth but also extended the median survival time by an additional 11 days compared to oHSV (armed with GFP as a control) combined with PD-1 antibody treatment, with some mice achieving complete tumor regression. Conclusions: Our findings confirm the potential of combining oncolytic viral therapy with 4-1BB targeting in enhancing the treatment of pancreatic cancer. Full article

(This article belongs to the Special Issue Immunotherapy for Cancers)

15 pages, 2216 KiB

Open AccessArticle

Monitoring the Risk of Type-2 Circulating Vaccine-Derived Poliovirus Emergence During Roll-Out of Type-2 Novel Oral Polio Vaccine

by Corey M. Peak, Hil Lyons, Arend Voorman, Elizabeth J. Gray, Laura V. Cooper, Isobel M. Blake, Kaija M. Hawes and Ananda S. Bandyopadhyay

Vaccines 2024, 12(12), 1308; https://doi.org/10.3390/vaccines12121308 - 22 Nov 2024

Abstract

Background/Objectives: Although wild poliovirus type 2 has been eradicated, the prolonged transmission of the live- attenuated virus contained in the type-2 oral polio vaccine (OPV2) in under-immunized populations has led to the emergence of circulating vaccine-derived poliovirus type 2 (cVDPV2). The novel OPV2 [...] Read more.

Background/Objectives: Although wild poliovirus type 2 has been eradicated, the prolonged transmission of the live- attenuated virus contained in the type-2 oral polio vaccine (OPV2) in under-immunized populations has led to the emergence of circulating vaccine-derived poliovirus type 2 (cVDPV2). The novel OPV2 (nOPV2) was designed to be more genetically stable and reduce the chance of cVDPV2 emergence while retaining comparable immunogenicity to the Sabin monovalent OPV2 (mOPV2). This study aimed to estimate the relative reduction in the emergence risk due to the use of nOPV2 instead of mOPV2. Methods: Data on OPV2 vaccination campaigns from May 2016 to 1 August 2024 were analyzed to estimate type-2 OPV-induced immunity in children under 5 years of age. Poliovirus surveillance data were used to estimate seeding dates and classify cVDPV2 emergences as mOPV2- or nOPV2-derived. The expected number of emergences if mOPV2 was used instead of nOPV2 was estimated, accounting for the timing and volume of nOPV2 doses, the known risk factors for emergence from mOPV2, and censoring due to the incomplete observation period for more recent nOPV2 doses. Results: As of 1 August 2024, over 98% of the approximately 1.19 billion nOPV2 doses administered globally were in Africa. We estimate that approximately 76 (95% confidence interval 69–85) index isolates of cVDPV2 emergences would be expected to be detected by 1 August 2024 if mOPV2 had been used instead of nOPV2 in Africa. The 18 observed nOPV2-derived emergences represent a 76% (74–79%) lower risk of emergence by nOPV2 than mOPV2 in Africa. The crude global analysis produced similar results. Key limitations include the incomplete understanding of the drivers of heterogeneity in emergence risk across geographies and variance in the per-dose risk of emergence may be incompletely captured using known risk factors. Conclusions: These results are consistent with the accumulating clinical and field evidence showing the enhanced genetic stability of nOPV2 relative to mOPV2, and this approach has been implemented in near-real time to contextualize new findings during the roll-out of this new vaccine. While nOPV2 has resulted in new emergences of cVDPV2, the number of cVDPV2 emergences is estimated to be approximately four-fold lower than if mOPV2 had been used instead. Full article

(This article belongs to the Special Issue Recent Scientific Development of Poliovirus Vaccines)

► Show Figures

Figure 1

13 pages, 991 KiB

Open AccessArticle

The Impact of Obesity on Influenza Vaccine Immunogenicity and Antibody Transfer to the Infant During Pregnancy

by Michelle Clarke, Suja M. Mathew, Lynne C. Giles, Ian G. Barr, Peter C. Richmond and Helen S. Marshall

Vaccines 2024, 12(12), 1307; https://doi.org/10.3390/vaccines12121307 - 22 Nov 2024

Abstract

Background/Objectives: Influenza vaccination is recommended for pregnant women, offering the dual benefit of protecting pregnant women and their newborn infants against influenza. This study aimed to investigate the impact of body mass index (BMI) on influenza vaccine responses in pregnant women and their [...] Read more.

Background/Objectives: Influenza vaccination is recommended for pregnant women, offering the dual benefit of protecting pregnant women and their newborn infants against influenza. This study aimed to investigate the impact of body mass index (BMI) on influenza vaccine responses in pregnant women and their newborns. Methods: Participants included pregnant women attending the Women’s and Children’s Hospital in South Australia between 2018 and 2021. Maternal blood samples were collected prior to and at 1 and 6 months post-influenza vaccination to measure antibody responses by hemagglutination inhibition (HI) assay. Cord blood samples were also collected. The percentages of participants achieving HI titre ≥40 were compared between obese and non-obese groups. Results: A total of 73 women were enrolled and received quadrivalent influenza vaccination at a mean age of 32 years (range 21–44 y) and median gestation of 24 weeks (range 11–37 weeks). BMI at vaccination was ≥30 kg/m² for 21/73 women (29%). Most pregnant women demonstrated antibody titres ≥ 40 to all four influenza vaccine strains at 1 month post-vaccination regardless of BMI category (BMI ≥ 30 kg/m²: 19/20; 95% vs. BMI < 30 kg/m²: 47/49; 96%). At 6 months post-vaccination, 12/17 (71%) obese women compared to 36/43 (84%) non-obese women (p = 0.25) maintained HI titres ≥ 40. Cord blood serology showed HI titres ≥ 40 for 11/17 (65%) infants born to mothers with BMI ≥ 30 compared to 30/35 (86%) infants delivered by mothers with BMI < 30 kg/m². Conclusions: A high BMI did not impair influenza vaccine antibody responses in pregnant women at 1 month post-vaccination. However, at 6 months post-vaccination, and in the cord blood samples, the percentages maintaining HI titre ≥ 40 were lower for obese women than for non-obese pregnant women. Full article

(This article belongs to the Special Issue The Recent Development of Influenza Vaccine: 2nd Edition)

► Show Figures

Figure 1

10 pages, 671 KiB

Open AccessCommentary

Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?

by Haozhe Cui and Eyad Elkord

Vaccines 2024, 12(12), 1306; https://doi.org/10.3390/vaccines12121306 - 22 Nov 2024

Abstract

The discovery of immune checkpoints (ICs) has pushed cancer treatment into the next era. As an emerging immune checkpoint, the TIGIT/CD155 axis inhibits the cytotoxicity of T and NK cells through multiple pathways. Immune checkpoint inhibitors (ICIs) targeting TIGIT are hopefully expected to [...] Read more.

The discovery of immune checkpoints (ICs) has pushed cancer treatment into the next era. As an emerging immune checkpoint, the TIGIT/CD155 axis inhibits the cytotoxicity of T and NK cells through multiple pathways. Immune checkpoint inhibitors (ICIs) targeting TIGIT are hopefully expected to address the issue of unresponsiveness to anti-PD-(L)1 monoclonal antibodies (mAbs) by combination therapy. This paper presents insights on the expression, structure and mechanism of action of TIGIT, as well as the principles and methods of designing mAbs targeting TIGIT and their clinical data. The advantages and disadvantages of targeting TIGIT using mAbs, bispecific and tri-specific antibodies (bsAbs and tsAbs), peptides, and compounds, in addition to potential combination therapies of anti-TIGIT with anti-PD-1 or cancer vaccines, are addressed. Finally, perspectives on current immunotherapies targeting TIGIT are discussed. Full article

(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy: Latest Advances, Limitations and Prospects)

► Show Figures

Figure 1

14 pages, 779 KiB

Open AccessArticle

How Attribution of COVID-19 Crisis Responsibility Predicts Hong Kong Citizens’ Intention to Accept Vaccination

by Ji Won Kim, Qinxian Cai, Lang Kao and Yi-Hui Christine Huang

Vaccines 2024, 12(12), 1305; https://doi.org/10.3390/vaccines12121305 - 22 Nov 2024

Abstract

Background: This study aims to illuminate the role of perceived crisis responsibility in shaping vaccination intention. By using the case of Hong Kong during the COVID-19 pandemic, we examined whether and how the allocation of crisis responsibility to the government predicts the public’s [...] Read more.

Background: This study aims to illuminate the role of perceived crisis responsibility in shaping vaccination intention. By using the case of Hong Kong during the COVID-19 pandemic, we examined whether and how the allocation of crisis responsibility to the government predicts the public’s intention to take vaccines, particularly by investigating its underlying mechanism. Method and Results: Based on a population-representative sample of Hong Kong adults (N = 3188), our results indicated that (1) the attribution of crisis responsibility directly led to lower vaccination intention, and (2) it also had indirect influences on vaccination intention through trust and anger; specifically, the crisis attribution resulted in less willingness to take vaccines via a decreased trust in government health agencies. We also found a serial mediation pathway in which anger aroused by the crisis attribution could decrease trust, which, in turn, yielded lower vaccination intentions. Conclusion: The findings of this study offer theoretical insights into the role of attribution of crisis responsibility in affecting vaccination decisions during a public health emergency. Further, these findings provide directions for crisis managers and public health authorities to develop communication strategies to motivate vaccine uptake and formulate an approach to tackle the pandemic crisis. Full article

(This article belongs to the Special Issue Vaccine Acceptance and Coverage)

► Show Figures

Figure 1

13 pages, 3223 KiB

Open AccessArticle

Live Attenuated aTJ Vaccine Effectively Protects Pigeons Against Homologous PPMV-1 Challenge

by Shan Zhang, Dahu Liu, Baojing Liu, Ruinying Liang, Lin Liang, Xinming Tang, Shaohua Hou, Chan Ding, Xusheng Qiu and Jiabo Ding

Vaccines 2024, 12(12), 1304; https://doi.org/10.3390/vaccines12121304 - 22 Nov 2024

Abstract

Background: Pigeon paramyxovirus type 1 (PPMV-1) is a significant pathogen affecting pigeon populations globally. The commonly used La Sota vaccine provides limited protection due to antigenic divergence from circulating PPMV-1 strains. An antigenically matched vaccine is needed to address this challenge. Methods: An [...] Read more.

Background: Pigeon paramyxovirus type 1 (PPMV-1) is a significant pathogen affecting pigeon populations globally. The commonly used La Sota vaccine provides limited protection due to antigenic divergence from circulating PPMV-1 strains. An antigenically matched vaccine is needed to address this challenge. Methods: An attenuated aTJ strain was developed through reverse genetics by modifying the F protein cleavage site of the virulent TJ-WT strain. Pigeons were immunized twice with the aTJ strain via eyedrop and intranasal routes, followed by a challenge with a virulent PPMV-1 strain ten days after the booster immunization. Results: The attenuated aTJ strain induced robust serum antibody titers post-booster immunization, and vaccinated pigeons showed strong protection upon challenge, with significantly reduced morbidity, mortality, and viral shedding compared to controls. Conclusions: These findings suggest that the aTJ strain is a promising candidate for the promotion of PPMV-1 prevention and control, emphasizing the importance of antigenic matching in optimizing vaccine efficacy. Full article

(This article belongs to the Special Issue Vaccines against Poultry Viruses)

► Show Figures

Figure 1

14 pages, 728 KiB

Open AccessArticle

The Real-World Effectiveness of Inactivated COVID-19 Vaccines in Zimbabwe During the Omicron Variant Dominance: A Test-Negative Case–Control Study

by Azure Tariro Makadzange, Patricia Gundidza, Kimberly Cheryl Chido Konono, Margaret Gurumani and Chiratidzo Ndhlovu

Vaccines 2024, 12(12), 1303; https://doi.org/10.3390/vaccines12121303 - 22 Nov 2024

Abstract

Background/Objectives: The COVID-19 pandemic has significantly impacted global health, with varying vaccine effectiveness (VE) across different regions and vaccine platforms. In Africa, where vaccination rates are relatively low, inactivated vaccines like BBIP-CorV (Sinopharm) and Coronovac (Sinovac) have been widely used. This study evaluated [...] Read more.

Background/Objectives: The COVID-19 pandemic has significantly impacted global health, with varying vaccine effectiveness (VE) across different regions and vaccine platforms. In Africa, where vaccination rates are relatively low, inactivated vaccines like BBIP-CorV (Sinopharm) and Coronovac (Sinovac) have been widely used. This study evaluated the real-world effectiveness of licensed inactivated COVID-19 vaccines in Zimbabwe during a period dominated by Omicron variants. Methods: We conducted a prospective, test-negative, case–control study among symptomatic adults across six Zimbabwean provinces from November 2022 to October 2023. Participants were categorized based on vaccination status, and nasopharyngeal swabs were collected for SARS-CoV-2 PCR testing. Vaccine effectiveness was assessed using conditional logistic regression, adjusting for various covariates such as age, sex, and comorbidities. Results: Among 5175 participants, 701 tested positive for SARS-CoV-2 and 4474 tested negative. The overall adjusted VE against symptomatic COVID-19 was 31% (95% CI: 5.3–49.7%) among verified vaccinated individuals. Boosted individuals demonstrated a higher VE of 59.8% (95% CI: 40.3–72.9%). VE decreased significantly to 24% (95% CI: −4.1–44.8%) in individuals vaccinated over a year prior. Similar VE was observed for BBIP-CorV (36.8%, 95% CI: 11.4–54.9%) and Coronovac (38.1%, 95% CI: 16.3–54.2%). Conclusions: This study indicates modest protection from inactivated COVID-19 vaccines against symptomatic Omicron infection, with significant enhancement following booster doses. These findings highlight the need for continued vaccine evaluation, particularly in resource-limited settings, to inform public health strategies and optimize vaccination programs. Full article

(This article belongs to the Special Issue COVID-19 Vaccination and Public Health: Addressing Global, Regional and Within-Country Inequalities)

► Show Figures

Figure 1

23 pages, 6553 KiB

Open AccessArticle

The Safety and Efficacy of New DIVA Inactivated Vaccines Against Lumpy Skin Disease in Calves

by Gaetano Federico Ronchi, Mariangela Iorio, Anna Serroni, Marco Caporale, Lilia Testa, Cristiano Palucci, Daniela Antonucci, Sara Capista, Sara Traini, Chiara Pinoni, Ivano Di Matteo, Caterina Laguardia, Gisella Armillotta, Francesca Profeta, Fabrizia Valleriani, Elisabetta Di Felice, Giovanni Di Teodoro, Flavio Sacchini, Mirella Luciani, Chiara Di Pancrazio, Michele Podaliri Vulpiani, Emanuela Rossi, Romolo Salini, Daniela Morelli, Nicola Ferri, Maria Teresa Mercante and Mauro Di Ventura Show full author list Hide full author list

Vaccines 2024, 12(12), 1302; https://doi.org/10.3390/vaccines12121302 - 21 Nov 2024

Abstract

Background: Lumpy skin disease virus (Poxviridae family—Capripoxvirus genus) is the aetiological agent of LSD, a disease primarily transmitted by hematophagous biting, affecting principally cattle. Currently, only live attenuated vaccines are commercially available, but their use is limited to endemic areas. There [...] Read more.

Background: Lumpy skin disease virus (Poxviridae family—Capripoxvirus genus) is the aetiological agent of LSD, a disease primarily transmitted by hematophagous biting, affecting principally cattle. Currently, only live attenuated vaccines are commercially available, but their use is limited to endemic areas. There is a need for safer vaccines, especially in LSD-free countries. This research aims to develop and test a safe and efficacious inactivated vaccine. Moreover, in this study, we used keyhole limpet hemocyanin (KLH) as a positive marker to distinguish infected from vaccinated animals (DIVA). Methods: Lumpy skin disease virus was propagated on primary lamb testis cells and Madin–Darby bovine kidney cells (PLT and MDBK, respectively), and four inactivated vaccines were produced. The vaccines differed from each other with the addition or not of KLH and in cells used for virus propagation. To evaluate the safety and immunogenicity, the vaccines and two placebos were administered to six groups comprising six male calves each, and antibody response was investigated using both an enzyme-linked immunosorbent assay (ELISA) and a serum neutralization (SN) test. In addition, the LSD/γ-interferon test and KLH (IgM-IgG) ELISA were performed on the collected samples. Furthermore, the use of KLH allowed us to distinguish vaccinated animals in the ELISA results, without any interference on the strength of the immune response against the LSDV. Finally, the efficacy of one of four vaccines was investigated through a challenge, in which one group of vaccinated animals and one animal control group were infected with a live field strain of LSDV. Results: Four out of the six control animals showed severe clinical signs suggestive of LSD, and, therefore, were euthanized for overcoming the predetermined limit of clinical score. By contrast, the vaccinated animals showed only mild symptoms, suggesting a reduction in severe disease notwithstanding the incapability of the vaccine in reducing the virus shedding. Conclusion: The vaccines produced were safe and able to elicit both a humoral and a cellular immune response, characteristics that, together with the demonstrated efficacy, make our vaccine a good candidate for countering the LSD spread in disease-free countries, thus also facilitating disease containment throughout the application of a DIVA strategy. Full article

(This article belongs to the Section Veterinary Vaccines)

► Show Figures

Figure 1

14 pages, 300 KiB

Open AccessArticle

Attitude Towards Vaccination Among University Students at a Spanish University: Relationships with Sociodemographic and Academic Variables

by Francisco Javier Pérez-Rivas, Laura Esteban-Gonzalo and David García-García

Vaccines 2024, 12(12), 1301; https://doi.org/10.3390/vaccines12121301 - 21 Nov 2024

Abstract

Objectives: This descriptive, cross-sectional study examines the attitude towards vaccination of students at the Complutense University of Madrid (Spain) and explores its relationship with sociodemographic and academic variables using a bivariate analysis and linear and logistic regression. Methods: The attitude towards vaccination of [...] Read more.

Objectives: This descriptive, cross-sectional study examines the attitude towards vaccination of students at the Complutense University of Madrid (Spain) and explores its relationship with sociodemographic and academic variables using a bivariate analysis and linear and logistic regression. Methods: The attitude towards vaccination of 3577 students of different disciplines was assessed using an online version of the Questionnaire on Attitudes and Behaviours towards Vaccination. In addition, all students were asked if they sought information produced by anti-vaccination groups and whether they identified as “anti-vaccine”. Results: In general, the students showed a favourable attitude towards vaccination. Older students, those in paid employment, and those undertaking non-health-related studies had less favourable attitudes. Spanish-born and female students showed more positive attitudes than foreign-born and non-binary/male students, respectively. Only a small proportion of students identified as anti-vaccine. Conclusions: Despite these positive results, the need for interventions targeting specific groups with less favourable attitudes, such as older students, employed students, and those in non-health-related fields, is clear. Full article

(This article belongs to the Special Issue Acceptance and Hesitancy in Vaccine Uptake)

27 pages, 1709 KiB

Open AccessArticle

Safety, Immunogenicity and Protective Activity of a Modified Trivalent Live Attenuated Influenza Vaccine for Combined Protection Against Seasonal Influenza and COVID-19 in Golden Syrian Hamsters

by Ekaterina Stepanova, Victoria Matyushenko, Daria Mezhenskaya, Ekaterina Bazhenova, Tatiana Kotomina, Alexandra Rak, Svetlana Donina, Anna Chistiakova, Arina Kostromitina, Vlada Novitskaya, Polina Prokopenko, Kristina Rodionova, Konstantin Sivak, Kirill Kryshen, Valery Makarov, Larisa Rudenko and Irina Isakova-Sivak

Vaccines 2024, 12(12), 1300; https://doi.org/10.3390/vaccines12121300 - 21 Nov 2024

Abstract

Background/Objectives: Influenza viruses and SARS-CoV-2 are currently cocirculating with similar seasonality, and both pathogens are characterized by a high mutational rate which results in reduced vaccine effectiveness and thus requires regular updating of vaccine compositions. Vaccine formulations combining seasonal influenza and SARS-CoV-2 strains [...] Read more.

Background/Objectives: Influenza viruses and SARS-CoV-2 are currently cocirculating with similar seasonality, and both pathogens are characterized by a high mutational rate which results in reduced vaccine effectiveness and thus requires regular updating of vaccine compositions. Vaccine formulations combining seasonal influenza and SARS-CoV-2 strains can be considered promising and cost-effective tools for protection against both infections. Methods: We used a licensed seasonal trivalent live attenuated influenza vaccine (3×LAIV) as a basis for the development of a modified 3×LAIV/CoV-2 vaccine, where H1N1 and H3N2 LAIV strains encoded an immunogenic cassette enriched with conserved T-cell epitopes of SARS-CoV-2, whereas a B/Victoria lineage LAIV strain was unmodified. The trivalent LAIV/CoV-2 composition was compared to the classical 3×LAIV in the golden Syrian hamster model. Animals were intranasally immunized with the mixtures of the vaccine viruses, twice, with a 3-week interval. Immunogenicity was assessed on day 42 of the study, and the protective effect was established by infecting vaccinated hamsters with either influenza H1N1, H3N2 or B viruses or with SARS-CoV-2 strains of the Wuhan, Delta and Omicron lineages. Results: Both the classical 3×LAIV and 3×LAIV/CoV-2 vaccine compositions induced similar levels of serum antibodies specific to all three influenza strains, which resulted in comparable levels of protection against challenge from either influenza strain. Protection against SARS-CoV-2 challenge was more pronounced in the 3×LAIV/CoV-2-immunized hamsters compared to the classical 3×LAIV group. These data were accompanied by the higher magnitude of virus-specific cellular responses detected by ELISPOT in the modified trivalent LAIV group. Conclusions: The modified trivalent live attenuated influenza vaccine encoding the T-cell epitopes of SARS-CoV-2 can be considered a promising tool for combined protection against seasonal influenza and COVID-19. Full article

(This article belongs to the Special Issue The Recent Development of Influenza Vaccine: 2nd Edition)

17 pages, 5223 KiB

Open AccessArticle

Geospatial Variation in Vaccination Coverage and Zero-Dose Prevalence at the District, Ward and Health Facility Levels Before and After a Measles Vaccination Campaign in Nigeria

by C. Edson Utazi, Iyanuloluwa D. Olowe, H. M. Theophilus Chan, Winfred Dotse-Gborgbortsi, John Wagai, Jamila A. Umar, Sulaiman Etamesor, Brian Atuhaire, Biyi Fafunmi, Jessica Crawford, Adeyemi Adeniran and Andrew J. Tatem

Vaccines 2024, 12(12), 1299; https://doi.org/10.3390/vaccines12121299 - 21 Nov 2024

Abstract

Many measles endemic countries with suboptimal coverage levels still rely on vaccination campaigns to fill immunity gaps and boost control efforts. Depending on local epidemiological patterns, national or targeted campaigns are implemented, following which post-campaign coverage surveys (PCCSs) are conducted to evaluate their [...] Read more.

Many measles endemic countries with suboptimal coverage levels still rely on vaccination campaigns to fill immunity gaps and boost control efforts. Depending on local epidemiological patterns, national or targeted campaigns are implemented, following which post-campaign coverage surveys (PCCSs) are conducted to evaluate their performance, particularly in terms of reaching previously unvaccinated children. Due to limited resources, PCCS surveys are designed to be representative at coarse spatial scales, often masking important heterogeneities in coverage that could enhance the identification of areas of poor performance for follow-up via routine immunization strategies. Here, we undertake geospatial analyses of the 2021 measles PCCS in Nigeria to map indicators of coverage measuring the individual and combined performance of the campaign and routine immunization (RI) at 1 × 1 km resolution and the ward and district levels in 13 states. Using additional geospatial datasets, we also produced estimates of numbers of unvaccinated children during the campaign and numbers of measles-containing vaccine (MCV) zero-dose children before and after the campaign at these levels and within health facility catchment areas. Our study revealed that although the campaign reduced the numbers of MCV zero-dose children in all the districts, areas of suboptimal campaign and RI performance with considerable numbers of zero-dose children remained. Our analyses further identified wards and health facility catchment areas with higher numbers of unvaccinated children within these areas. Our outputs provide a robust evidence base to plan and implement follow-up RI strategies and to guide future campaigns at flexible and operationally relevant spatial scales. Full article

(This article belongs to the Section Human Vaccines and Public Health)

► Show Figures

Figure 1

12 pages, 1880 KiB

Open AccessSystematic Review

Association Between Influenza Vaccine and Immune Thrombocytopenia: A Systematic Review and Meta-Analysis

by Zhicai Liu, Jing Wang, Zhaojun Lu, Yuyang Xu, Jian Du, Jiayin Han, Xuechao Zhang and Yan Liu

Vaccines 2024, 12(11), 1298; https://doi.org/10.3390/vaccines12111298 - 20 Nov 2024

Abstract

Background: Immune thrombocytopenia (ITP) is an uncommon but serious adverse reaction after vaccination. However, its association with vaccines other than the measles–mumps–rubella vaccine remains debatable. This study aimed to analyze ITP cases following influenza vaccination and assess any potential association. Methods: We performed [...] Read more.

Background: Immune thrombocytopenia (ITP) is an uncommon but serious adverse reaction after vaccination. However, its association with vaccines other than the measles–mumps–rubella vaccine remains debatable. This study aimed to analyze ITP cases following influenza vaccination and assess any potential association. Methods: We performed a systematic search of the Web of Science, Embase, and PubMed databases from their inception to 15 April 2024. Cases were characterized qualitatively, and relative risk was assessed using either fixed or random models. Results: A total of 24 studies were analyzed, including 16 patients from 14 case reports. Patients averaged 56.7 years old, half were female, and ten patients had a history of prior illness. The mean time between vaccination and diagnosis was 13.3 days. Treatment primarily involved corticosteroids or intravenous immunoglobulin, with most recovering within a month. The pooled odds ratio for ITP post-influenza vaccination was 0.94 (95%CI: 0.85–1.03). Subgroup analyses conducted according to the study design and vaccine type did not reveal any significant results. Conclusion: No evidence of an association between influenza vaccination and ITP was found. Further observational studies are required to verify this relationship. Full article

(This article belongs to the Special Issue Influenza Virus Vaccines and Vaccination)

► Show Figures

Figure 1

14 pages, 2430 KiB

Open AccessArticle

Preliminary Study on Type I Interferon as a Mucosal Adjuvant for Human Respiratory Syncytial Virus F Protein

by Hongqiao Hu, Li Zhang, Lei Cao, Jie Jiang, Yuqing Shi, Hong Guo, Yang Wang, Hai Li and Yan Zhang

Vaccines 2024, 12(11), 1297; https://doi.org/10.3390/vaccines12111297 - 20 Nov 2024

Abstract

Background: Human respiratory syncytial virus (HRSV) imposes a significant disease burden on infants and the elderly. Intranasal immunization using attenuated live vaccines and certain vector vaccines against HRSV has completed phase II clinical trials with good safety and efficacy.Recombinant protein vaccines for mucosal [...] Read more.

Background: Human respiratory syncytial virus (HRSV) imposes a significant disease burden on infants and the elderly. Intranasal immunization using attenuated live vaccines and certain vector vaccines against HRSV has completed phase II clinical trials with good safety and efficacy.Recombinant protein vaccines for mucosal immunization require potent mucosal adjuvants. Type I interferon (IFN), as a natural mucosal adjuvant, significantly enhances antigen-presenting cell processing and antigen presentation, promoting the production of T and B cells. Methods: This study utilized human α2b interferon (IFN-human) and mouse α2 interferon (IFN-mouse) as nasal mucosal adjuvants in combination with fusion protein (F). Intranasal immunization was performed on BALB/c mice to evaluate the immunogenicity of the formulation in vivo. Results: Compared to the F protein immunization group, mice in the F + IFN-Human and F + IFN-Mouse experimental groups exhibited significantly increased neutralizing antibody titers and augmented secretion of IFN-γ and IL-4 by lymphocytes, and both of them could induce the production of high-titer specific IgA antibodies in mice (p < 0.001).The F + IFN-Human immunization induced the highest IgG and IgG1 antibody titers in mice; however, the F + IFN-Mouse immunization group elicited the highest neutralizing antibody titers (598), lowest viral loads in the lungs (Ct value of 31), and fastest weight recovery in mice. Moreover, mice in the F + IFN-Mouse immunization group displayed the mildest lung pathological damage (Total score of pathological injury was 2). Conclusions: In conclusion, IFN-Mouse, as a mucosal adjuvant for HRSV recombinant protein vaccines, demonstrated superior protective effects in mice compared to IFN-Human adjuvants. Full article

► Show Figures

Figure 1

14 pages, 10252 KiB

Open AccessReview

Childhood Mandatory Vaccinations: Current Situation in European Countries and Changes Occurred from 2014 to 2024

by Sara Farina, Alessandra Maio, Maria Rosaria Gualano, Walter Ricciardi and Leonardo Villani

Vaccines 2024, 12(11), 1296; https://doi.org/10.3390/vaccines12111296 - 20 Nov 2024

Abstract

Background/Objectives: Vaccination is one of the most effective public health interventions, preventing millions of deaths globally each year. However, vaccine hesitancy, driven by misinformation and reduced disease risk perception, has led to declining vaccination rates and the resurgence of vaccine-preventable diseases (VPDs) [...] Read more.

Background/Objectives: Vaccination is one of the most effective public health interventions, preventing millions of deaths globally each year. However, vaccine hesitancy, driven by misinformation and reduced disease risk perception, has led to declining vaccination rates and the resurgence of vaccine-preventable diseases (VPDs) in Europe. In response to this, countries have implemented various strategies, including mandatory and recommended vaccination programs. The objective of this study is to map the current European landscape of pediatric vaccination policies, and the variations that have occurred in the last decade. Methods: This rapid review was conducted on PubMed, Google, and the European Centre for Disease Prevention and Control website, to collect all vaccination schedules in EU/EEA countries in 2024 and all documents focusing on the introduction of mandatory vaccines during the last decade. Results: As of 2024, 13 countries had at least one mandatory pediatric vaccination, with France, Hungary, and Latvia requiring all but one vaccine. In contrast, 17 countries had no mandatory vaccinations, relying only on recommendations. Between 2014 and 2024, six countries (Croatia, France, Germany, Hungary, Italy, and Poland) introduced or extended mandatory vaccinations. Conclusions: European vaccination policies show significant variation. Effective programs depend on robust healthcare systems, public trust, and adaptable strategies to address vaccine hesitancy and the resurgence of VPDs. Full article

(This article belongs to the Special Issue Advance Public Health through Vaccination)

► Show Figures

Figure 1

14 pages, 1260 KiB

Open AccessArticle

Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021–May 2023

by Camelia Savulescu, Albert Prats-Uribe, Kim Brolin, Zvjezdana Lovrić Makarić, Anneli Uusküla, Georgios Panagiotakopoulos, Colm Bergin, Catherine Fleming, Antonella Agodi, Paolo Bonfanti, Rita Murri, Viesturs Zvirbulis, Dace Zavadska, Konstanty Szuldrzynski, Ausenda Machado, Corneliu Petru Popescu, Mihai Craiu, Maria Cisneros, Miriam Latorre-Millán, Goranka Petrović, Liis Lohur, Kyriaki Tryfinopoulou, Jonathan McGrath, Lauren Ferguson, Martina Barchitta, Anna Spolti, Katleen de Gaetano Donati, Ilze Abolina, Dagne Gravele, Vânia Gaio, Simin Aysel Florescu, Mihaela Lazar, Pilar Subirats, Laura Clusa Cuesta, Gordan Sarajlić, Marina Amerali, Jacklyn Sui, Claire Kenny, Venerando Rapisarda, Marianna Rossi, Silvia Lamonica, Dainis Krievins, Elza Anna Barzdina, Ana Palmira Amaral, Alma Gabriela Kosa, Victor Daniel Miron, Carmen Muñoz-Almagro, Ana María Milagro, Sabrina Bacci, Piotr Kramarz, Anthony Nardone and the VEBIS HCW VE Study Group Show full author list Hide full author list

Vaccines 2024, 12(11), 1295; https://doi.org/10.3390/vaccines12111295 - 19 Nov 2024

Abstract

Background: European countries have included healthcare workers (HCWs) among priority groups for COVID-19 vaccination. We established a multi-country hospital network to measure the SARS-CoV-2 incidence and effectiveness of COVID-19 vaccines among HCWs against laboratory-confirmed SARS-CoV-2 infection. Methods: HCWs from 19 hospitals in 10 [...] Read more.

Background: European countries have included healthcare workers (HCWs) among priority groups for COVID-19 vaccination. We established a multi-country hospital network to measure the SARS-CoV-2 incidence and effectiveness of COVID-19 vaccines among HCWs against laboratory-confirmed SARS-CoV-2 infection. Methods: HCWs from 19 hospitals in 10 countries participated in a dynamic prospective cohort study, providing samples for SARS-CoV-2 testing at enrolment and during weekly/fortnightly follow-up. We measured the incidence during pre-Delta (2 May–6 September 2021), Delta (7 September–14 December 2021), and Omicron (15 December 2021–2 May 2023) waves. Using Cox regression, we measured the relative vaccine effectiveness (rVE) of the first COVID-19 booster dose versus primary course alone during Delta and Omicron waves. Results: We included a total of 3015 HCWs. Participants were mostly female (2306; 79%), with a clinical role (2047; 68%), and had a median age of 44 years. The overall incidence of SARS-CoV-2 infection was 3.01/10,000 person-days during pre-Delta, 4.21/10,000 during Delta, and 23.20/10,000 during Omicron waves. rVE was 59% (95% CI: −25; 86) during Delta and 22% (1; 39) during Omicron waves. rVE was 51% (30; 65) 7–90 days after the first booster dose during the Omicron wave. Conclusions: The incidence of SARS-CoV-2 infection among HCWs was higher during the Omicron circulation period. The first COVID-19 vaccine booster provided additional protection against SARS-CoV-2 infection compared to primary course vaccination when recently vaccinated <90 days. This multi-country HCW cohort study addressing infection as the main outcome is crucial for informing public health interventions for HCWs. Full article

(This article belongs to the Special Issue COVID Vaccines: Design, Development, and Immune Response Studies: 2nd Edition)

► Show Figures

Figure 1

16 pages, 2872 KiB

Open AccessProtocol

Multiparameter Flow Cytometric Analysis of the Conventional and Monocyte-Derived DC Compartment in the Murine Spleen

by Ronald A. Backer, Hans Christian Probst and Björn E. Clausen

Vaccines 2024, 12(11), 1294; https://doi.org/10.3390/vaccines12111294 - 19 Nov 2024

Abstract

Dendritic cells (DCs) are present in almost all tissues, where they act as sentinels involved in innate recognition and the initiation of adaptive immune responses. The DC family consists of several cell lineages that are heterogenous in their development, phenotype, and function. Within [...] Read more.

Dendritic cells (DCs) are present in almost all tissues, where they act as sentinels involved in innate recognition and the initiation of adaptive immune responses. The DC family consists of several cell lineages that are heterogenous in their development, phenotype, and function. Within these DC lineages, further subdivisions exist, resulting in smaller, less characterized subpopulations, each with its unique immunomodulatory capabilities. Given the interest in utilizing DC for experimental studies and for vaccination purposes, it becomes increasingly crucial to thoroughly classify and characterize these diverse DC subpopulations. This understanding is vital for comprehending their relative contribution to the initiation, regulation, and propagation of immune responses. To facilitate such investigation, we here provide an easy and ready-to-use multicolor flow cytometry staining panel for the analysis of conventional DC, plasmacytoid DC, and monocyte-derived DC populations isolated from mouse spleens. This adaptable panel can be easily customized for the analysis of other tissue-specific DC populations, providing a valuable tool for DC research. Full article

(This article belongs to the Special Issue Dendritic Cells (DCs) and Cancer Immunotherapy)

► Show Figures

Figure 1

14 pages, 681 KiB

Open AccessReview

Human Papillomavirus (HPV) Vaccination: Progress, Challenges, and Future Directions in Global Immunization Strategies

by Francesco Branda, Grazia Pavia, Alessandra Ciccozzi, Angela Quirino, Nadia Marascio, Simona Gigliotti, Giovanni Matera, Chiara Romano, Chiara Locci, Ilenia Azzena, Noemi Pascale, Daria Sanna, Marco Casu, Giancarlo Ceccarelli, Massimo Ciccozzi and Fabio Scarpa

Vaccines 2024, 12(11), 1293; https://doi.org/10.3390/vaccines12111293 - 19 Nov 2024

Abstract

Human papillomavirus (HPV) is a widespread viral pathogen, responsible for a significant burden of cervical and other cancers worldwide. Over the past decades, the development and widespread adoption of prophylactic HPV vaccines have dramatically reduced the incidence of HPV-related diseases. However, despite the [...] Read more.

Human papillomavirus (HPV) is a widespread viral pathogen, responsible for a significant burden of cervical and other cancers worldwide. Over the past decades, the development and widespread adoption of prophylactic HPV vaccines have dramatically reduced the incidence of HPV-related diseases. However, despite the efficacy of these vaccines, global immunization efforts still face several obstacles, including low vaccination coverage in low- and middle-income countries, vaccine hesitancy, and disparities in access to healthcare. This review aims to provide a comprehensive overview of the current state of HPV vaccines, including their mechanisms of action, safety profiles, and real-world efficacy. We will explore the impact of HPV vaccines on cancer prevention, examine the challenges related to vaccine distribution and uptake, and assess the role of public health policies in improving global vaccination rates. Additionally, the review will highlight the latest advancements in therapeutic HPV vaccines, ongoing research into next-generation vaccines, and the potential of HPV vaccination strategies in the context of personalized medicine. By examining these factors, we aim to provide insights into the future directions of HPV vaccination and its role in global public health. Full article

(This article belongs to the Special Issue Vaccines and Vaccination: HIV, Hepatitis Viruses, and HPV)

► Show Figures

Figure 1

19 pages, 3264 KiB

Open AccessArticle

Sindbis Virus Replicon-Based SARS-CoV-2 and Dengue Combined Vaccine Candidates Elicit Immune Responses and Provide Protective Immunity in Mice

by Yihan Zhu, Wenfeng He, Rui Hu, Xiahua Liu, Mengzhu Li and Yuan Liu

Vaccines 2024, 12(11), 1292; https://doi.org/10.3390/vaccines12111292 - 19 Nov 2024

Abstract

Background/Objectives: Since its emergence in 2019, the rapid spread of SARS-CoV-2 led to the global pandemic. Recent large-scale dengue fever outbreaks overlapped with the COVID-19 pandemic, leading to increased cases of co-infection and posing severe public health risks. Accordingly, the development of [...] Read more.

Background/Objectives: Since its emergence in 2019, the rapid spread of SARS-CoV-2 led to the global pandemic. Recent large-scale dengue fever outbreaks overlapped with the COVID-19 pandemic, leading to increased cases of co-infection and posing severe public health risks. Accordingly, the development of effective combined SARS-CoV-2 and dengue virus (DENV) vaccines is necessary to control the spread and prevalence of both viruses. Methods: In this study, we designed Sindbis virus (SINV) replicon-based SARS-CoV-2 and DENV chimeric vaccines using two delivery strategies: DNA-launched self-replicating RNA replicon (DREP) and viral replicon particle (VRP) systems. Results: Cellular and animal experiments confirmed that the vaccines effectively produced viral proteins and elicited strong immunogenicity. These vaccines induced robust immune responses and neutralizing activity against live SARS-CoV-2, DENV1, and DENV2 viruses. In addition, passively transferred sera from BALB/c mice immunized with these vaccines into AG129 mice provided significant protection against lethal DENV2 challenge. The transferred sera protected the mice from physical symptoms, reduced viral loads in the kidney, spleen, liver, and intestine, and prevented DENV2-induced vascular leakage in these tissues. Conclusions: Therefore, combined vaccines based on the SINV replicon system are promising candidates for pandemic control. These results lay a foundation for further development of a safe and effective combination vaccine against SARS-CoV-2 and DENV. Full article

(This article belongs to the Section COVID-19 Vaccines and Vaccination)

► Show Figures

Figure 1

22 pages, 359 KiB

Open AccessReview

Human Papillomavirus-Related Cancer Vaccine Strategies

by Xia Cai and Ling Xu

Vaccines 2024, 12(11), 1291; https://doi.org/10.3390/vaccines12111291 - 19 Nov 2024

Abstract

Background: Human papillomavirus (HPV) persistent infection is a major pathogenic factor for HPV-related cancers, such as cervical cancer (CC), vaginal cancer, vulvar cancer, anal cancer, penile cancer, and head and neck cancer (HNC). Since the introduction of the world’s first prophylactic HPV vaccine, [...] Read more.

Background: Human papillomavirus (HPV) persistent infection is a major pathogenic factor for HPV-related cancers, such as cervical cancer (CC), vaginal cancer, vulvar cancer, anal cancer, penile cancer, and head and neck cancer (HNC). Since the introduction of the world’s first prophylactic HPV vaccine, there has been a decline in the incidence of HPV infections and associated cancers. This article reviews the latest literature on the research progress, efficacy, and safety of HPV vaccines for these cancers, providing a reference for HPV vaccination strategy. Methods: By utilizing databases such as PubMed, Google Scholar, CNKI, and Wanfang, we conducted a literature search on research papers related to HPV vaccines from 2014 to 2024, employing keywords such as “HPV”, “HPV vaccine”, “CC”, ”vaginal cancer”, “vulvar cancer”, “anal cancer”, “penile cancer” and “HNC”. Additionally, we reviewed the latest information available on official websites, including the World Health Organization (WHO). Based on the quality and relevance of the papers, we selected over 100 of the most representative articles for further summarization and analysis. Results: Vaccination against HPV can effectively block the transmission of the virus and prevent HPV-related cancers. Current studies have confirmed the efficacy and safety of prophylactic HPV vaccination. However, numerous challenges remain. The global vaccination rate for preventive vaccines remains low, particularly in low- and middle-income countries. Nonetheless, in the future, we can enhance the accessibility, affordability, and coverage of HPV vaccines by expanding the indications of already licensed vaccines, continuously developing new vaccines. Conclusions: The HPV vaccine is an extremely effective measure for the prevention and treatment of HPV-related cancers. Although there are many challenges in expanding the coverage of the HPV vaccine. It is believed that in the not-too-distant future, both prophylactic and therapeutic HPV vaccines will achieve commendable results. Full article

(This article belongs to the Special Issue Vaccine Strategies for HPV-Related Cancers)

Journal Description

Vaccines

Latest Articles

Journal Menu

Journal Browser

Highly Accessed Articles

Latest Books

E-Mail Alert

News

Topics

Conferences

Special Issues

Topical Collections

Further Information

Guidelines

MDPI Initiatives

Follow MDPI